Ex-vivo Effect of New Oral Anticoagulants on Point-of-care Devices

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Prof. Dr. E. Lindhoff-Last, Johann Wolfgang Goethe University Hospitals
ClinicalTrials.gov Identifier:
NCT01613443
First received: June 5, 2012
Last updated: November 1, 2012
Last verified: November 2012
  Purpose

Concentration determinations of anticoagulants require plasma instead of whole blood, and results are not immediately available to clinicians. Monitoring anticoagulants concentration along with bedside methods may provide an alternative guide for administration of the NOAC.

The purpose of this investigation is to compare bedside coagulation assays in whole blood with plasma concentrations of the new oral anticoagulants (NOAC) in patients treated with therapeutic dosis of NOAC.


Condition
Effect of NOAC on POCT

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Time-dependent ex Vivo Influence of Rivaroxaban on Point-of-care Devices

Resource links provided by NLM:


Further study details as provided by Johann Wolfgang Goethe University Hospitals:

Enrollment: 100
Study Start Date: June 2012
Groups/Cohorts
Control
Healthy volunteers without medication
Phenprocoumon
Patients receiving Marcumar having target INR 2-3
Dabigatran
Patients receiving therapeutic dosis of Pradaxa
Rivaroxaban
Patients receiving therapeutic dosis of Xarelto

Detailed Description:

This open-label study will be performed by ex vivo investigations. Patients receiving the NOAC as dabigatran or rivaroxaban in therapeutic doses are recruited and informed consent of two blood sampling times will be obtained in correlation to the time of drug intake (two and 24 hours after drug intake). The bedside measurements will be performed and compared directly with the concentrations determined by plasma concentration assays. These investigations will be performed at the department of Angiology at the university hospital Frankfurt.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients indicated for NOAC-therapy

Criteria

The indication for the use of NOAC is provided by the attending physician. The criteria for inclusion and exclusion criteria for the use of the new oral anticoagulants must meet appropriate eligibility criteria and the clinical guidelines that are described in the SOPs.

Patients treated with dabigatran 2x150mg / d for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation are included.

Moreover, patients treated with rivaroxaban 20 mg / d for DVT prophylaxis and treatment of recurrent DVT or PE are included.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Prof. Dr. E. Lindhoff-Last, Prof. Dr. med. Lindhoff-Last, Johann Wolfgang Goethe University Hospitals
ClinicalTrials.gov Identifier: NCT01613443     History of Changes
Other Study ID Numbers: POCT-NOAC
Study First Received: June 5, 2012
Last Updated: November 1, 2012
Health Authority: Germany: Ethics Commission

Keywords provided by Johann Wolfgang Goethe University Hospitals:
Dabigatran, Rivaroxaban, Point of Care-testing

Additional relevant MeSH terms:
Rivaroxaban
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 22, 2014